AbbVie, a major biopharmaceutical company, just picked up biotech startup Stemcentrx in a deal that’s worth up to $10.2 billion.That would make it the second-largest venture capital-backed acquisition in history. The startup, which had previously been valued at $5 billion, is developing drugs that target cancer stem cells, a specific type of cancer cell that some research suggests could play a key role in defeating the disease.
Read more: http://snapzu.com/drunkenninja/heres-why-pharma-giant-abbvie-coughed-up-10-billion-to-buy-a-startup-youve-never-heard-of
No comments:
Post a Comment